Vivesto AB (ST:VIVE) — Market Cap & Net Worth
Market Cap & Net Worth: Vivesto AB (VIVE)
Vivesto AB (ST:VIVE) has a market capitalization of $5.59 Million (Skr51.93 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28137 globally and #629 in its home market, demonstrating a 6.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vivesto AB's stock price Skr0.08 by its total outstanding shares 618177586 (618.18 Million). Analyse how efficiently does Vivesto AB generate cash to see how efficiently the company converts income to cash.
Vivesto AB Market Cap History: 2015 to 2026
Vivesto AB's market capitalization history from 2015 to 2026. Data shows change from $442.85 Million to $5.59 Million (-36.80% CAGR).
Vivesto AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vivesto AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
28.45x
Vivesto AB's market cap is 28.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $442.85 Million | $6.37 Million | -$141.54 Million | 69.49x | N/A |
| 2016 | $382.56 Million | $172.00K | -$160.24 Million | 2224.17x | N/A |
| 2017 | $114.82 Million | $3.17 Million | -$118.01 Million | 36.23x | N/A |
| 2018 | $400.98 Million | $1.98 Million | -$171.02 Million | 202.51x | N/A |
| 2019 | $275.42 Million | $201.84 Million | -$10.53 Million | 1.36x | N/A |
| 2020 | $274.09 Million | $201.84 Million | -$10.53 Million | 1.36x | N/A |
| 2021 | $174.50 Million | $26.19 Million | -$138.94 Million | 6.66x | N/A |
| 2022 | $28.87 Million | $1.01 Million | -$367.03 Million | 28.45x | N/A |
Competitor Companies of VIVE by Market Capitalization
Companies near Vivesto AB in the global market cap rankings as of May 4, 2026.
Key companies related to Vivesto AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Vivesto AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Vivesto AB's market cap moved from $442.85 Million to $ 5.59 Million, with a yearly change of -36.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr5.59 Million | -37.78% |
| 2025 | Skr8.98 Million | -53.45% |
| 2024 | Skr19.29 Million | -28.83% |
| 2023 | Skr27.11 Million | -6.11% |
| 2022 | Skr28.87 Million | -83.45% |
| 2021 | Skr174.50 Million | -36.33% |
| 2020 | Skr274.09 Million | -0.48% |
| 2019 | Skr275.42 Million | -31.31% |
| 2018 | Skr400.98 Million | +249.23% |
| 2017 | Skr114.82 Million | -69.99% |
| 2016 | Skr382.56 Million | -13.61% |
| 2015 | Skr442.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Vivesto AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.59 Million USD |
| MoneyControl | $5.59 Million USD |
| MarketWatch | $5.59 Million USD |
| marketcap.company | $5.59 Million USD |
| Reuters | $5.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more